Intracameral Gas SF6 (Sulfur Hexafluoride) Injection for Acute Hydrops in Keratoconus

Hydrops in Keratoconus Clinical Trial

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00593190
• Other study ID #: 0097-07-EMC
• Status: Completed
• Phase: N/A
• Start date: January 2008
• Est. completion date: May 2010

Study information

• Verified date: February 2020
• Source: HaEmek Medical Center, Israel
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Intracameral Gas SF6 (Sulfur Hexafluoride) Injection for Acute Hydrops in Keratoconus

Recruitment information / eligibility

• Status: Completed
• Enrollment: 8
• Est. completion date: May 2010
• Est. primary completion date: December 2008
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Hydrops

Exclusion Criteria:

• Age < 18 years old

Related Conditions & MeSH terms

• Edema
• Hydrops in Keratoconus
• Keratoconus

Intervention

Drug:
• Gas SF6 (Sulfur Hexafluoride)
ONCE

Locations

Country	Name	City	State
Israel	HaEmek Medical Center	Afula

Sponsors (1)

Lead Sponsor	Collaborator
HaEmek Medical Center, Israel

Country where clinical trial is conducted

Israel, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Hydrops resulotion		weeks